Loading…
Adagene Inc. is projected to rise to $4.93 by 2027, a +25% move from its current price of $3.94. ADAG is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.77 | $3.94 | $4.13 | +0.06% |
| Jul 14 | $3.70 | $3.94 | $4.21 | +0.12% |
| Jul 15 | $3.65 | $3.95 | $4.27 | +0.18% |
| Jul 16 | $3.60 | $3.95 | $4.33 | +0.24% |
| Jul 17 | $3.57 | $3.95 | $4.38 | +0.31% |
| Jul 18 | $3.53 | $3.95 | $4.42 | +0.37% |
| Jul 19 | $3.51 | $3.96 | $4.47 | +0.43% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.51 | $3.96 | $4.47 | +0.43% |
| Week 2 | $3.35 | $3.97 | $4.72 | +0.86% |
| Week 3 | $3.23 | $3.99 | $4.92 | +1.29% |
| Week 4 | $3.14 | $4.01 | $5.11 | +1.73% |
| Week 5 | $3.07 | $4.03 | $5.28 | +2.16% |
| Week 6 | $3.00 | $4.04 | $5.44 | +2.60% |
| Week 7 | $2.95 | $4.06 | $5.60 | +3.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Adagene Inc. is a clinical stage biotechnology company focused on the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. It was incorporated in 2011 and is headquartered in Suzhou, China.
Its lead product candidate is ADG126, a masked fully-human anti-CTLA-4 mAb in phase 1b/2 clinical development for cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; and ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors. ADG104, an anti-PD-L1 monoclonal antibody, is in phase 2 clinical development, and ADG125, a novel anti-CSF-1R mAb, is in Phase 2 clinical development.
In addition, it is developing ADG138, a HER2xCD3 POWERbody in preclinical trial to treat low expressing tumors and resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody in preclinical trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 SAFEbody, in preclinical trial for hematologic and solid tumors; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Adagene Inc. (ADAG) operates in the Healthcare sector and is listed with a current price of $3.93. The stock carries a market capitalization of $259.67M and is ranked 3579 by market cap.
The price outlook reflects a multi-year forecast that shows a path from a neutral to bullish trajectory, with the 2026 average price at $3.93 and progressively higher averages in subsequent years. The forecast highlights rising averages and notable ROIs later in the horizon, culminating in substantial upside by 2050.
A major floor 37.2% below — a decisive break under it would weaken the trend.
The nearest floor, 17.3% below — buyers have tended to step in here.
The nearest ceiling, 21.3% above — a clean break opens room to run.
A major ceiling 39.9% above — clearing it would confirm fresh momentum.
Key ADAG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADAG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.90 | Buy | $3.96 | Sell |
| MA 10 | $4.13 | Sell | $4.01 | Sell |
| MA 20 | $3.97 | Sell | $3.96 | Sell |
| MA 50 | $3.76 | Buy | $3.81 | Buy |
| MA 100 | $3.69 | Buy | $3.55 | Buy |
| MA 200 | $2.84 | Buy | $3.11 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.53 | Neutral |
| Stoch RSI (14) | 10.64 | Buy |
| CCI (20) | -6.81 | Neutral |
| Williams %R (14) | -88.42 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -1.01 | Sell |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 11.58 | Buy |
| TRIX (15) | 0.49 | Buy |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 45.42 | Neutral |
| Momentum (10) | -0.18 | Sell |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 3.72 | Buy |
| ADX (14) | 12.83 | Neutral |
| ATR (14) | 0.16 | Info |
The 30-day technical picture shows a trading band from $2.80 to $5.51. RSI14 sits at 50, with a 50-day simple moving average of $3.73 and a 200-day simple moving average of $2.81. The near-term support is at $3.26 and resistance at $4.78.
These levels indicate a mid-range, with the stock oscillating within a modestly bullish framework over the last month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.53 | $3.94 | $5.22 | 0% | Neutral | |
| $3.68 | $4.93 | $7.12 | +25% | Bullish | |
| $4.50 | $6.35 | $9.70 | +61% | Bullish | |
| $6.04 | $8.89 | $14.19 | +126% | Bullish | |
| $6.03 | $9.23 | $15.27 | +134% | Bullish | |
| $6.06 | $9.61 | $16.40 | +144% | Bullish | |
| $7.01 | $11.50 | $20.17 | +192% | Bullish | |
| $6.29 | $10.65 | $19.15 | +170% | Bullish | |
| $6.93 | $12.11 | $22.27 | +207% | Bullish | |
| $9.69 | $17.45 | $32.79 | +343% | Bullish | |
| $11.18 | $23.24 | $47.62 | +490% | Bullish | |
| $28.28 | $62.84 | $144.53 | +14.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.53 | $3.94 | $4.73 | +0.00% |
| August 2026 | $3.36 | $4.04 | $5.05 | +2.66% |
| September 2026 | $3.42 | $4.17 | $5.29 | +2.99% |
| October 2026 | $3.20 | $3.94 | $5.08 | -5.51% |
| November 2026 | $3.05 | $3.79 | $4.94 | -3.84% |
| December 2026 | $3.16 | $3.95 | $5.22 | +4.45% |
Click any year to see its month-by-month ADAG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ADAG price prediction for 2026 points to an average of $3.94 (low $1.53, high $5.22) — a potential gain of 0% on today's $3.94. Price action looks broadly range-bound.
In 2027, ADAG is projected to trade between $3.68 and $7.12, averaging $4.93 — a potential gain of +25% from today's $3.94. That is up +25% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Adagene Inc.'s 2028 outlook centres on $6.35, within a $4.50 to $9.70 range. That is up +29% on the projected 2027 average. That marks a +61% change versus current levels. Momentum favours further upside here.
By 2029, ADAG could reach as high as $14.19, with a base case around $8.89 and support toward $6.04 — roughly +126% from $3.94. Buyers look set to stay in control over this stretch.
Expect ADAG to range from $6.03 to $15.27 through 2030. The $9.23 average target implies a +134% move from current prices. That is up +4% on the projected 2029 average. Momentum favours further upside here.
The ADAG price prediction for 2031 points to an average of $9.61 (low $6.06, high $16.40) — a potential gain of +144% on today's $3.94. Buyers look set to stay in control over this stretch.
In 2032, ADAG is projected to trade between $7.01 and $20.17, averaging $11.50 — a potential gain of +192% from today's $3.94. That is up +20% on the projected 2031 average. Momentum favours further upside here.
Adagene Inc.'s 2033 outlook centres on $10.65, within a $6.29 to $19.15 range. That is -7% versus the projected 2032 average. That marks a +170% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, ADAG could reach as high as $22.27, with a base case around $12.11 and support toward $6.93 — roughly +207% from $3.94. Momentum favours further upside here.
Expect ADAG to range from $9.69 to $32.79 through 2035. The $17.45 average target implies a +343% move from current prices. That is up +44% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ADAG price prediction for 2040 points to an average of $23.24 (low $11.18, high $47.62) — a potential gain of +490% on today's $3.94. Momentum favours further upside here.
In 2050, ADAG is projected to trade between $28.28 and $144.53, averaging $62.84 — a potential gain of +14.9x from today's $3.94. That is up +170% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ADAG today (≈ 253.807107 ADAG) could be worth
$15,948.64
+$14,948.64 (+1495%) by 2050 · US Dollar
Based on the average projected ADAG price of $62.84 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADAGwould be worth at today's price.
$1,000 invested in ADAG on Jul 10, 2025 (≈ 515.463902 ADAG) would be worth
$2,030.93
+$1,030.93 (+103.1%) today · 2.03× · US Dollar
Based on a ADAG entry price of $1.94 vs. today's $3.94.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.47 | $881.43 | -11.9% |
| 1 month ago | $3.32 | $1,186.75 | +18.7% |
| 3 months ago | $3.8 | $1,036.84 | +3.7% |
| 6 months ago | $1.59 | $2,477.99 | +147.8% |
| 1 year ago | $1.94 | $2,030.93 | +103.1% |
| All time (5.0y) ago | $16.85 | $233.83 | -76.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADAG forecast.
Our base-case forecast reaches $7.90 around 2029.
Implied market cap at $7.90: $521.97M
The multi-year forecast envisions a bullish trajectory after 2026, with the following annual averages and ROIs: 2026 avg $3.93 (ROI 0, sentiment NEUTRAL); 2027 avg $4.59 (ROI 16.8, NEUTRAL); 2028 avg $5.79 (ROI 47.4, BULLISH); 2029 avg $8.22 (ROI 109.3, BULLISH); 2030 avg $8.29 (ROI 110.8, BULLISH).
Further out, 2031 avg $8.47 (ROI 115.5, BULLISH); 2032 avg $10.02 (ROI 155.1, BULLISH); 2033 avg $8.73 (ROI 122.2, BULLISH); 2034 avg $9.75 (ROI 148.1, BULLISH); 2035 avg $14.38 (ROI 266, BULLISH).
By 2040, the avg price is projected to be $18.17 with ROI 362.4 and a BULLISH sentiment. In 2050, the avg price is projected at $48.18 with ROI 1125.8 and a BULLISH sentiment. These are estimates, not guarantees, and reflect potential upside over a long horizon along with inherent investment uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $8.29 with a min of $5.20, a max of $14.20 and a projected ROI of 110.8%, with a BULLISH sentiment.
Forecasts show a bullish trajectory after 2026, with rising averages and ROIs, including 2029 avg $8.22 (ROI 109.3) and 2050 avg $48.18 (ROI 1125.8), though these are estimates and not guarantees.
Yes. The 2032 forecast is an average of $10.02 with a min of $5.80 and a max of $18.30, yielding an ROI of 155.1 and a bullish outlook.
Current price is $3.93 and market cap is $259.67M, with a rank of 3579.
The 30-day range is $2.80 to $5.51. Near-term indicators include RSI14 at 50, SMA50 at $3.73, SMA200 at $2.81, with support at $3.26 and resistance at $4.78.
Adagene Inc. Community Discussion
0Share your Adagene Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.